Fujifilm's CDMO carves foothold in Boston biotech hub with new HQ focused on viral vectors, gene therapies

On the heels of a red-letter year for contract manufacturers, Japan’s Fujifilm has seen its CDMO arm — Fujifilm Diosynth Biotechnologies — earn interest from major Covid-19 vaccine makers for its viral-vector capabilities. Now, the drugmaker is looking to lock down its US footprint in the bustling Boston biotech hub.